© Globe Newswire
08.08.2025
ORNBV
LISTED
HEL
Orion Corporation: Managers’ transactions – Juhani Kankaanpää
News Preview
ORION CORPORATION MANAGERS’ TRANSACTIONS 8 AUGUST 2025 at 9.30 EEST ...
Themefolio
Profiler
Peergroup
© ActuNews
07.08.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgevingen van UBS Group AG
News Preview
Leuven, BELGIË – 7 augustus 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgevingen heeft ontvangen:
Oxurion ontving een transpa...
Themefolio
Profiler
Peergroup
© ActuNews
07.08.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notifications from UBS Group AG
News Preview
Leuven, BELGIUM – August 7, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:
Oxurion received a transparency notification on August 1, 2025, from UBS G...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© ActuNews
07.08.2025
OXUR
LISTED
EURONEXT
Oxurion beëindigt RD-programma voor geografische maculaire degeneratie en focust op nieuwe CRO-activiteiten
News Preview
Leuven, België, 7 augustus 2025, 18u00 – Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutische vennootschap gevestigd in Leuven, kondigt vandaag de definitieve stopzetting aan van zijn preklinisch onderzoeksprogramma gericht op de ontwikkeling van nieuwe therapeutische doelwitten voor geografische maculaire degeneratie (GA).
Dit pro...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ActuNews
07.08.2025
OXUR
LISTED
EURONEXT
Oxurion Ends RD Program in Geographic Atrophy and Refocuses on New CRO Activities
News Preview
Leuven, BELGIUM – August 7, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced the definitive termination of its preclinical research program aimed at developing new therapeutic targets for geographic atrophy (GA).
This program relied on a high-throughput gene...
Themefolio
Profiler
Peergroup
© ActuNews
07.08.2025
OXUR
LISTED
EURONEXT
Oxurion met fin à son programme de RD sur la dégénérescence maculaire géographique et se recentre sur ses nouvelles activités de CRO
News Preview
Louvain, Belgique, 7 août 2025, 18h00, Oxurion NV (Euronext Bruxelles : OXUR), entreprise biopharmaceutique basée à Louvain, annonce aujourd'hui la cessation définitive de son programme de recherche préclinique dédié au développement de nouvelles cibles thérapeutiques pour la d&eacut...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.08.2025
ZEAL
LISTED
CPH
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results
News Preview
Press Release – No. 11 / 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.08.2025
GMAB
LISTED
CPH
Genmab Announces Financial Results for the First Half of 2025
News Preview
August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.08.2025
GMAB
LISTED
CPH
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.08.2025
CELC
LISTED
NASDAQ
Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call
News Preview
MINNEAPOLIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2025 after the market closes on Thursday, August 14, 2025. Management will host a webcast/tel...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.08.2025
IMCR
LISTED
NASDAQ
Immunocore reports second quarter financial results and provides a business update
News Preview
KIMMTRAK® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year...
Themefolio
Profiler
Peergroup
© EQS Newswire
07.08.2025
AFX
LISTED
XETR
Carl Zeiss Meditec grows revenue and earnings in the first nine months of 2024/25
News Preview
Carl Zeiss Meditec grows revenue and earnings in the first nine months of 2024/25
Significant recovery and further expansion of order entry compared to prior year
JENA, 7 August 2025
Carl Zeiss Meditec generated revenue of €1,600.1m in the first nine months of fiscal year 2024/25 (prior year: €1,486.5m), including the DORC consolidation, c......
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
07.08.2025
AFX
LISTED
XETR
Carl Zeiss Meditec erzielt Umsatz- und Ergebniswachstum nach neun Monaten 2024/25
News Preview
Carl Zeiss Meditec erzielt Umsatz- und Ergebniswachstum nach neun Monaten 2024/25
Auftragseingang gegenüber Vorjahr weiter deutlich erholt und ausgebaut
JENA, 7. August 2025
Carl Zeiss Meditec erzielte in den ersten neun Monaten des Geschäftsjahres 2024/25 inklusive der DORC-Konsolidierung einen Umsatz von rund 1.600,1 Millionen Euro
(Vj. ......
Themefolio
Profiler
Peergroup
© Globe Newswire
07.08.2025
IBAB
LISTED
EURONEXT
IBA Notice of Half Year 2025 Results and Conference Call
News Preview
HY25 results webcast to take place on Thursday, 28 August 2025 at 3pm CEST...
Themefolio
Profiler
Peergroup
© ActuNews
06.08.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – August 6, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:
Oxurion received a transparency notification on August 6, 2025, from Atlas...
Themefolio
Profiler
Peergroup
© ActuNews
06.08.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 6 augustus 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgevingen heeft ontvangen:
Oxurion ontving een transpa...
Themefolio
Profiler
Peergroup
© EQS Newswire
06.08.2025
PHIA
LISTED
EURONEXT
Doctor-patient trust is key to unlocking AI's potential to improve healthcare in Australia, finds Philips' Future Health Index Report
News Preview
EQS Newswire / 06/08/2025 / 10:00 CET/CEST
Two-thirds (66%) of Australians welcome technology for improved care, but more than half (53%) are concerned it will mean less face time with their doctor. Three in four (74%) Australian healthcare professionals report losing clinical time due to incomplete or inaccessible patient data, ......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.08.2025
EVT
LISTED
XETR
Evotec SE to announce first half-year results 2025 on 13 August 2025
News Preview
Hamburg, Germany, 06 August 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) will announce its half-year interim report for the first six months of 2025 on Wednesday, 13 August 2025.
The Company is going to hold a conference call to discuss the results as well as provide an u......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.08.2025
EVT
LISTED
XETR
Bekanntgabe der Ergebnisse für das erste Halbjahr 2025 am 13. August 2025
News Preview
Hamburg, 06. August 2025:
Die Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) veröffentlicht am Mittwoch, 13. August 2025, ihren Halbjahresbericht für die ersten sechs Monate 2025.
In einer Telefonkonferenz in englischer Sprache werden die Ergebnisse und Schwerpunkte aus dem B......
Themefolio
Profiler
Peergroup
© ACCESS Newswire
06.08.2025
EVT
LISTED
XETR
Evotec SE to announce first half-year results 2025 on 13 August 2025
News Preview
HAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its half-year interim report for the first six months of 2025 on Wednesday, 13 August 2025.The Company is going to hold a conference call to discuss the results as well as p...
Themefolio
Profiler
Peergroup
© EQS Newswire
05.08.2025
EUZ
LISTED
XETR
Umsetzung des Aktiensplits durch Ausgabe von Gratisaktien erfolgt am 15. August 2025
News Preview
Berlin, 5. August 2025. Nachdem alle formellen Voraussetzungen des am 18. Juni 2025 von der Hauptversammlung beschlossenen Aktiensplits erfüllt sind, erfolgt nun die bankenseitige Umsetzung dieser Kapitalmaßnahme der Eckert & Ziegler SE (ISIN DE0005659700).
Danach stehen den Aktionären der Gesellschaft aufgrund ihres bisherigen Aktienbesitzes i......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.08.2025
EUZ
LISTED
XETR
Implementation of the Share Split by Issuing Bonus Shares to Be Effective on 15 August 2025
News Preview
Berlin, 5 August 2025. All formal requirements of the stock split resolved by the Annual General Meeting on 18 June 2025 have now been met and the timeline for implementation of this capital measure of Eckert & Ziegler SE (ISIN DE0005659700) on the bank side is set.
Accordingly, the company's shareholders will be entitled to new shares in the r......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.08.2025
1SXP
LISTED
XETR
SCHOTT Pharma reports preliminary results for Q3 2025 and specifies FY 2025 guidance
News Preview
SCHOTT Pharma reports preliminary results for Q3 2025 and specifies FY 2025 guidance
Q3 2025 revenues up 3% yoy at constant currencies to EUR 256m
Q3 2025 EBITDA up 11% yoy to EUR 83m, with a quarterly margin of 32.4% (31.7% at constant currencies)
Organic revenue growth for FY 2025 is expected to be around 6.0%, at the lower end of management e......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.08.2025
1SXP
LISTED
XETR
SCHOTT Pharma veröffentlicht vorläufiges Ergebnis für das dritte Quartal 2025 und präzisiert Prognose für das Geschäftsjahr 2025
News Preview
SCHOTT Pharma veröffentlicht vorläufiges Ergebnis für das dritte Quartal 2025 und präzisiert Prognose für das Geschäftsjahr 2025
Umsatz in Q3 2025 steigt währungsbereinigt um 3 % auf 256 Mio. Euro
EBITDA wächst in Q3 2025 um 11 % auf 83 Mio. Euro, die EBITDA Marge beträgt 32,4 % (31,7 % währungsbereinigt)
Das organische Wachstum für das Geschäft......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.08.2025
1SXP
LISTED
XETR
SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin
News Preview
SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin
SCHOTT Pharma specifies FY 2025 guidance:
Organic revenue growth for FY 2025 is expected to be around 6.0%, at the lower end of management expectations between 6.0% and 9.0% (“high-single digit”).
The EBITDA margin for FY 2025 is expected to be around 28.0%, above the p......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.08.2025
1SXP
LISTED
XETR
SCHOTT Pharma präzisiert die Prognose für Umsatzwachstum und EBITDA-Marge für das Geschäftsjahr 2025
News Preview
SCHOTT Pharma präzisiert die Prognose für Umsatzwachstum und EBITDA-Marge für das Geschäftsjahr 2025
SCHOTT Pharma präzisiert die Prognose für das Geschäftsjahr 2025:
Das organische Wachstum für das Geschäftsjahr 2025 wird ungefähr 6,0 % betragen, was am unteren Ende der Management-Erwartung von 6,0 % bis 9,0 % liegt („im hohen einstelligen Bereic......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.08.2025
GXI
LISTED
XETR
Gerresheimer separiert Moulded Glass und beabsichtigt anschließend einen Verkaufsprozess zu initiieren
News Preview
Gerresheimer separiert Moulded Glass und beabsichtigt anschließend einen Verkaufsprozess zu initiieren
Beste Wachstumschancen für Moulded Glass als starke, unabhängige Einheit mit acht Werken in Europa, Amerika und Asien
Weiterer Schritt in der Transformation der Gerresheimer zu einem reinen System- und Lösungsanbieter für die Pharma- und Biotech......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.08.2025
GXI
LISTED
XETR
Gerresheimer to Separate Moulded Glass and Intends to Initiate a Subsequent Sales Process
News Preview
Gerresheimer to Separate Moulded Glass and Intends to Initiate a Subsequent Sales Process
Best growth opportunities for Moulded Glass as a strong, independent unit with eight plants across Europe, the Americas and Asia
Further step in Gerresheimer's strategic transformation into a system and solution provider purely for the pharma and biotech in......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.08.2025
GXI
LISTED
XETR
Gerresheimer AG to Separate Moulded Glass and Intends to Initiate a Subsequent Sales Process
News Preview
Gerresheimer AG to Separate Moulded Glass and Intends to Initiate a Subsequent Sales Process
Duesseldorf, August 04, 2025. Gerresheimer AG (ISIN: DE000A0LD6E6, "Gerresheimer") has completed the strategic review of its moulded glass business and decided to separate the business and intends to subsequently initiate a sales process for the business u......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.08.2025
GXI
LISTED
XETR
Gerresheimer AG separiert Moulded Glass und beabsichtigt anschließend einen Verkaufsprozess zu initiieren
News Preview
Gerresheimer AG separiert Moulded Glass und beabsichtigt anschließend einen Verkaufsprozesses zu initiieren
Düsseldorf, 04. August 2025. Die Gerresheimer AG (ISIN: DE000A0LD6E6, „Gerresheimer“) hat die strategische Überprüfung ihres Moulded-Glass-Geschäfts abgeschlossen und entschieden, das Geschäft zu separieren und beabsichtigt anschließend, ei......
Themefolio
Profiler
Peergroup
© ActuNews
04.08.2025
OXUR
LISTED
EURONEXT
Oxurion obtient une offre de financement revue à la hausse à 30 M EUR pour lancer la diversification de sa trésorerie en actifs numériques
News Preview
Louvain, Belgique, 4 août 2025, 18h00, Oxurion NV (Euronext Bruxelles : OXUR), entreprise biopharmaceutique basée à Louvain, annonce avoir reçu une offre indicative de financement renforcée de la part d'Atlas Special Opportunities, portant sur un montant total de 30 millions d'euros.
Cette proposition pr&ea...
Themefolio
Profiler
Peergroup
© ActuNews
04.08.2025
OXUR
LISTED
EURONEXT
Oxurion kondigt aan dat het een verbeterd indicatief financieringsaanbod van EUR 30 miljoen heeft gekregen om de diversificatie van een deel van zijn kasmiddelen naar digitale activa te starten
News Preview
Leuven, BELGIË, 4 augustus 2025 – 18u00 CET – Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, kondigt aan dat het een verbeterd indicatief financieringsaanbod heeft ontvangen van Atlas Special Opportunities, voor een totaalbedrag van €30 miljoen.
De voorgestelde f...
Themefolio
Profiler
Peergroup
© ActuNews
04.08.2025
OXUR
LISTED
EURONEXT
Oxurion announces it obtained an improved indicative EUR 30 million financing offer to initiate its plan to diversify by allocating part of its treasury into digital assets
News Preview
Leuven, Belgium, August 4, 2025 – 06:00 PM CEST – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces that it has received an improved indicative financing offer from Atlas Special Opportunities for a total amount of €30 million.
The proposed financing would be structured in 10 successi...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.08.2025
MURA
LISTED
NASDAQ
Mural Oncology Announces Second Quarter Financial Results and Provides Business Update
News Preview
Mural continues to explore strategic alternatives...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.08.2025
FYB
LISTED
XETR
First Berlin Equity Research GmbH: Formycon AG | Rating: Buy
News Preview
Original-Research: Formycon AG - from First Berlin Equity Research GmbH
04.08.2025 / 11:45 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certai......
Themefolio
Profiler
Peergroup
© ActuNews
04.08.2025
OXUR
LISTED
EURONEXT
Oxurion finalise l'acquisition d'Axiodis CRO et accélère la structuration de son pôle européen dédié à la donnée clinique
News Preview
Oxurion annonce la réalisation complète de l'acquisition de 72?% du capital d'Axiodis CRO
Cette opération marque la première étape dans la constitution d'un pôle intégré centré sur la donnée clinique
Le Groupe intensifie les discussions avec d'autres cibles s...
Themefolio
Profiler
Peergroup
© ActuNews
04.08.2025
OXUR
LISTED
EURONEXT
Oxurion completes the acquisition of Axiodis CRO and accelerates the structuring of its European clinical data platform
News Preview
Oxurion announces the full completion of the acquisition of a 72% equity stake in Axiodis CRO
This transaction marks the first step in building an integrated platform focused on clinical data
The Group is intensifying discussions with additional strategic targets in France and across Europe
Leuven, Belgium, August 4, 2025 – 08:30 CEST &nd...
Themefolio
Profiler
Peergroup
© ActuNews
04.08.2025
OXUR
LISTED
EURONEXT
Oxurion rondt overname van Axiodis CRO af en versnelt uitbouw van haar Europese platform voor klinische data
News Preview
Oxurion kondigt de volledige afronding aan van de overname van 72% van het aandelenkapitaal van Axiodis CRO.
Deze overnamne vormt de eerste stap in de uitbouw van een geïntegreerd platform rond klinische data.
De Groep versnelt de gesprekken met aanvullende strategische partners in Frankrijk en de rest Europa.
Leuven, BELGIË, 4 augu...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.08.2025
DBV
LISTED
EURONEXT
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025
News Preview
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.08.2025
CLARI
LISTED
EURONEXT
Tap issue in the amount of €100M of its notes due June 27th, 2030, bringing its total amount to €500m
News Preview
...
Themefolio
Profiler
Peergroup
© BusinessWire
01.08.2025
OGI
LISTED
NASDAQ
Organigram to Report Third Quarter Fiscal 2025 Results on August 13, 2025
News Preview
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share, announced today it will report earnings results for its third quarter fiscal 2025 ended June 30, 2025, on Wednesday, August 13, 2025, prior to market open.
The Company will host a conference call to discuss its results...
Themefolio
Profiler
Peergroup
© EQS Newswire
31.07.2025
BAYN
LISTED
XETR
Bayer hebt währungsbereinigte Umsatz- und Ergebnisprognose für 2025 an und erhöht Rückstellungen für Rechtsstreitigkeiten in den USA
News Preview
Leverkusen, 31. Juli 2025 – Vor der Bekanntgabe der Geschäftsentwicklung des zweiten Quartals 2025 am Mittwoch, 6. August, informiert die Bayer AG über wesentliche Finanzkennzahlen. Für das Gesamtjahr 2025 hebt Bayer die währungsbereinigte (wb.) Umsatz- und Ergebnisprognose an, da sich das Geschäft der Division Pharmaceuticals im ersten Halbjahr be......
Themefolio
Profiler
Peergroup
© EQS Newswire
31.07.2025
BAYN
LISTED
XETR
Bayer upgrades currency-adjusted sales and earnings guidance for 2025 and establishes additional provisions for litigation in the United States
News Preview
Leverkusen, July 31, 2025 – Ahead of the publication of its business results for the second quarter of 2025 on Wednesday, August 6, Bayer AG is providing an update on key financial figures. Due to a better-than-expected business performance at Pharmaceuticals in the first half of the year, Bayer is raising its full-year guidance for currency-adjust......
Themefolio
Profiler
Peergroup
© BusinessWire
31.07.2025
DFTX
LISTED
NASDAQ
MindMed Reports Q2 2025 Financial Results and Business Updates
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its second quarter 2025 financial results and provided an update on business highlights.
“We continue making significant progress across al...
Themefolio
Profiler
Peergroup
© BusinessWire
31.07.2025
SLP
LISTED
NASDAQ
SLP Investors Have Opportunity to Join Simulations Plus, Inc. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Simulations Plus, Inc. (“Simulations Plus” or “the Company”) (NASDAQ: SLP) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2025
EAPI
LISTED
EURONEXT
Availability of 2025 Half-Year Financial Report
News Preview
Paris – July 31, 2025 – EUROAPI posted today its 2025 condensed Half-Year Consolidated Financial Statements for the six months ended June 30, 2025. This document is available for consultation and downloading on EUROAPI’s website: https://www.euroapi.com/en/investors/regulatory-information/financial-reports. ...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2025
BAVA
LISTED
CPH
Bavarian Nordic Announces Closing of Sale of Priority Review Voucher and Upgrades its 2025 Financial Guidance
News Preview
COPENHAGEN, Denmark, July 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the sale of its Priority Review Voucher (PRV). Upon completion, the company received a cash consideration of USD 160 million....
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2025
TFX
LISTED
NYSE
Teleflex Announces Quarterly Dividend
News Preview
WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 15, 2025, to shareholders of record at the close of business on August 15, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2025
TIL
LISTED
NASDAQ
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
News Preview
Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2025
IMCR
LISTED
NASDAQ
Immunocore to report second quarter 2025 financial results and host call on August 7, 2025
News Preview
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, July 31, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases a...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2025
FAGR
LISTED
EURONEXT
Fagron delivers strong performance with 11% topline growth and 12% increase in REBITDA for H1 2025
News Preview
...
Themefolio
Profiler
Peergroup
© ActuNews
30.07.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt aangepaste transparantiekennisgeving van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 30 juli 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen:
Oxurion ontving een transparanti...
Themefolio
Profiler
Peergroup
© ActuNews
30.07.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – July 30, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
Oxurion received a transparency notification on July 29, 2025, from Atlas...
Themefolio
Profiler
Peergroup
© ActuNews
30.07.2025
OXUR
LISTED
EURONEXT
OXURION : Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie
News Preview
Atlas Special Opportunities, LLC heeft 12 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 300.000. Deze conversie vormt deel van Atlas Special Opportunities, LLC's EUR 20 miljoen kapitaaltoezegging1 die aan Oxurion zal toelaten om te focussen op het ontwikkelen van innovatieve geneesmiddelen om h...
Themefolio
Profiler
Peergroup
© ActuNews
30.07.2025
OXUR
LISTED
EURONEXT
OXURION : Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
News Preview
Atlas Special Opportunities, LLC has converted 12 convertible bonds in Oxurion resulting in a EUR 300,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential m...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.07.2025
ORY
LISTED
BME
ORYZON Reports Financial Results and Corporate Update for Half-Year Ending June 30, 2025
News Preview
MADRID and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today reported financial results for the half-year ended June 30, 2025 and provided a corporate update on recent developments....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.07.2025
SKYE
LISTED
NASDAQ
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
News Preview
SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, August 7, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss its second quarter 2025 f...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.07.2025
MDGL
LISTED
NASDAQ
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
News Preview
CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical Group Limited (HKEX Stock CodeL 1093) (“CSPC”) for SYH2086, a preclinical oral small molecule glucagon-like peptide-1 (GLP-1) recept...
Themefolio
Profiler
Peergroup
© EQS Newswire
30.07.2025
EVT
LISTED
XETR
Evotec und Sandoz entwickeln ihre strategische Partnerschaft weiter und vereinbaren einen möglichen Verkauf des Just – Evotec Biologics Standorts in Toulouse
News Preview
Evotec SE und Sandoz AG haben ein nicht-bindendes Term Sheet über den geplanten Verkauf von Just – Evotec Biologics EU in Toulouse an Sandoz unterzeichnet
Im Rahmen der vorgeschlagenen Vereinbarung würde Evotec ihre Ressourcen zur Herstellung von Biosimilars übertragen, um Sandoz die Produktion von Biosimilar-Arzneimitteln unter Verwend......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.07.2025
EVT
LISTED
XETR
Evotec and Sandoz evolve their strategic partnership and agree on potential sale of Just – Evotec Biologics Toulouse site
News Preview
Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just – Evotec Biologics EU in Toulouse to Sandoz
Under the proposed deal Evotec would transfer biosimilar manufacturing capabilities to enable Sandoz to produce biosimilar medicines using Just – Evotec Biologics’ advanced continuous manufacturing technology
......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
